SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Allergan Ligand (ALRI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: songw who wrote (29)9/2/1997 11:12:00 PM
From: Andrew H   of 46
 
No we didn't miss it. Have been discussing little else on the LGND thread.

However, I did not see the "50% success rate" you mention. The release specified 4 of 5 new case remissions and 4 of 12 previously treated case remissions, for a total of 8 of 18 or 44%. Not bad.

What I found really terrific was the 80% rate for new patients (100% if you don't count the patient who died from complications). This leads me to believe panretin will be the treatment of choice for ALL newly diagnosed patients.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News